Takeda Pharmaceutical Company Limited (TAK)
| Market Cap | 51.08B |
| Revenue (ttm) | 51.66B |
| Net Income (ttm) | 4.09B |
| Shares Out | 3.12B |
| EPS (ttm) | 1.31 |
| PE Ratio | 24.58 |
| Forward PE | 9.73 |
| Dividend | $1.38 (8.41%) |
| Ex-Dividend Date | Sep 29, 2022 |
| Volume | 949,430 |
| Open | 16.36 |
| Previous Close | 16.47 |
| Day's Range | 16.33 - 16.51 |
| 52-Week Range | 12.28 - 16.58 |
| Beta | 0.69 |
| Analysts | Buy |
| Price Target | 18.90 (+15.49%) |
| Earnings Date | May 10, 2023 |
About TAK
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Repla... [Read more]
Full Company ProfileFinancial Performance
In 2022, TAK's revenue was 3.57 trillion, an increase of 11.61% compared to the previous year's 3.20 trillion. Earnings were 230.06 billion, a decrease of -38.81%.
Financial numbers in JPY Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for TAK stock is "Buy." The 12-month stock price forecast is $18.9, which is an increase of 15.49% from the latest price.
News
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...
Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today confirmed that the New England Journal of Medicine (NEJM) has published positive data from the Phase 4 EARNEST study ...
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that its Board of Directors today decided that it will propose a new candidate for independent external director at the 147th Ordina...
InvoX Pharma's F-star Announces Licence Agreement With Takeda for Second Novel Next-Generation Immuno-Oncology Bispecific Antibody
LONDON--(BUSINESS WIRE)--F-star, an invoX company, has entered into a second licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody
Price Growth & Yield: For That Magical Combo, Leave the U.S.
It's not often you find one stock with sustained price growth and solid dividend yield, but three foreign stocks, Takeda Pharmaceutical Co., Ltd. (NYSE: TAK), United Microelectronics Corp. (NYSE: UMC)...
Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting
BOSTON--(BUSINESS WIRE)--Results from the Phase 2b clinical trial of TAK-279 (formerly NDI-034858), a novel allosteric TYK2 inhibitor developed by Nimbus Therapeutics and owned by Takeda (TSE:4502/NYS...
Big Stocks Making New Highs Despite Everything
Interest rates may be headed higher and regional banks may be in trouble but that hasn't stopped just a few stocks from hitting new highs.
Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced positive results from a Phase 2b clinical trial of TAK-279 (NDI-034858), a highly selective, oral allosteri...
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...
For Takeda Pharmaceutical's CFO, 'Speed and Agility' Were Key to Shire Tie-Up
Costa Saroukos, who became Takeda's global finance chief in 2018, discusses why moving fast after an acquisition is crucial in melding company cultures and cutting back debt.
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating ved...
Takeda Completes Acquisition of Nimbus Therapeutics' TYK2 Program Subsidiary
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. (“Lakshmi”) from Nimbus Therapeu...
Nimbus Therapeutics Announces Closing of Takeda's Acquisition of TYK2 Subsidiary
BOSTON--(BUSINESS WIRE)--Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug...
U.S. FDA Approves Takeda's TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda ( TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applic...
Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the third quarter of fiscal year 2022 (period ended December 31, 2022).
Takeda inks deal with Hutchmed for up to $1.1 billion
Takeda Pharmaceutical Co. Ltd. TAK, +0.43% 4502, +0.65% said Monday that it will acquire Hutchmed's HCM, +1.46% 13, +1.10% experimental cancer treatment outside mainland China, Hong Kong and Macau, wi...
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED's Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with HUTCHMED (China) Limited (Nasdaq/AIM: HCM,...
Takeda Named Global Top Employer for Sixth Consecutive Year
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda ( TSE:4502/NYSE:TAK) today announced that, for the sixth consecutive year, it was one of only 15 companies to achieve global Top Employer® c...
Takeda's EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that EXKIVITY® (mobocertinib) has been approved by the National Medical Products Administration (NMPA) of...
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
OSAKA, Japan & CAMBRIDGE, Mass. & PASADENA, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced topline results from the Phase 2 SEQ...
Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the totality of evidence from a pre-planned interim analysis of a pivotal Phase 3 study supports the...
Takeda's Phase 3 AURORA Study Provides Evidence of Maribavir's Clinically Meaningful and Durable Effect in Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Patients, Despite Missing Primary Endpoint
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that in the AURORA trial, a Phase 3, multicenter, randomized, double-blind, double-dummy, active-controll...
Takeda to Acquire Nimbus Therapeutics' Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases
BOSTON--(BUSINESS WIRE)--Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a clinical-stage company that designs and develops breakthrough medicines through its powerful computational dr...
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda ( TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric t...